Recommendations for the transfusion management of patients in the perioperative period. I. The pre-operative period

Blood Transfusion

Volumn 9, Issue 1, 2011, Pages 19-30

  Liumbruno, Giancarlo Maria ^a,f   Bennardello, Francesco ^b   Lattanzio, Angela ^c   Piccoli, Pierluigi ^d   Rossetti, Gina ^e  

^a SAN GIOVANNI CALIBITA FATEBENEFRATELLI HOSPITAL   (Italy)

^b CIVILE M P AREZZO HOSPITAL   (Italy)

^c Service of Immunohaematology and Transfusion Medicine   (Italy)

^d Hospital of Verona   (Italy)

^e Trento Hospital   (Italy)

^f NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACENOCOUMAROL; ACETYLSALICYLIC ACID; ANTITHROMBIN; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 7A; CLOPIDOGREL; DESMOPRESSIN; DIPYRIDAMOLE; HEPARIN; IRON; TICLOPIDINE; WARFARIN;

ANTITHROMBIN DEFICIENCY; ARTICLE; BLEEDING; BLEEDING DISORDER; BLOOD TRANSFUSION; HEMATOCRIT; HEMOSTASIS; HUMAN; LABORATORY TEST; LOW DRUG DOSE; PARTIAL THROMBOPLASTIN TIME; PREOPERATIVE CARE; PROPHYLAXIS; PROTHROMBIN TIME; RISK FACTOR; THROMBOCYTE COUNT; THROMBOCYTE DISORDER; THROMBOCYTOPENIA;

BLOOD TRANSFUSION; FEMALE; HUMANS; MALE; PERIOPERATIVE CARE; PERIOPERATIVE PERIOD;

EID: 78751505594     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2010.0074-10     Document Type: Article

References (128)

1. Goodnough LT, Shander A. Blood management. Arch Pathol Lab Med 2007; 131: 695-701.
2. Chee YL, Crawford JC, Watson HG, Greaves M. Guidelines on the assessment of bleeding risk prior to surgery or invasive procedures. Br J Haematol 2008; 140: 496-504.
3. American Society of Anesthesiologists Task Force on Perioperative Blood Transfusion and Adjuvant Therapies. Practice guidelines for perioperative blood transfusion and adjuvant therapies: An updated report by the American Society of Anesthesiologists Task Force on Perioperative Blood Transfusion and Adjuvant Therapies. Anesthesiology 2006; 105: 198-208.
4. Goodnough LT, Shander A, Spivak JL, et al. Detection, evaluation, and management of anemia in the elective surgical patient. Anesth Analg 2005; 101: 1858-61.
5. Koh MBC, Beverley J. The management of perioperative bleeding. Blood Rev 2003; 17: 179-85.
6. Dean JA, Blanchette VS, Carcao MD, et al. von Willebrand disease in a pediatric-based population: Comparison of type 1 diagnostic criteria and use of the PFA-100® and a von Willebrand factor/collagen binding assay. Thromb Haemost 2000; 3: 401-9.
7. Ferraris VA, Ferraris SP, Saha SP, et al. Perioperative blood transfusion and blood conservation in cardiac surgery: The Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists Clinical Practice Guidelines. Ann Thorac Surg 2007; 83: S27-86.
8. Drews CD, Dilley AB, Lally C, et al. Screening question to identify women with von Willebrand Disease. J Am Med Women Assoc 2002; 57: 217-8.
9. Laffan M, Brown SA, Collins PW, et al. The diagnosis of von Willebrand disease: A guideline from the UK Haemophilia Centre Doctors' Organization. Haemophilia 2004; 10: 199-217. (Pubitemid 38584792)
10. Lee JW. Von Willebrand disease, hemophilia A and hemophilia B, and other factor deficiencies. Int Anesthesiol Clin 2004; 42: 59-76.
11. Zahreddine I, Atassi K, Fuhrman C, et al. Impact of prior biological assessment of coagulation on the hemorrhagic risk of fiberoptic bronchoscopy. Rev Mal Respir 2003; 20: 341-6.
12. Tosetto A, Rodeghiero F, Castaman G, et al. Aquantitative analysis of bleeding symptoms in type 1 von Willebrand disease: Results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost 2006; 4: 766-73.
13. Rodeghiero F, Castaman G, Tosetto A, et al. The discriminant power of bleeding history for the diagnosis of von Willebrand disease type 1: An international, multicenter study. J Thromb Haemost 2005; 3: 2619-26.
14. Higham JM, O'Brien PM, Shav RW. Assessment of menstrual blood loss using a pictorial chart. Br J Obstet Gynaecol 1990; 97: 734-9.
15. James AH, Kouides PA, Abdul-Kadir R, et al. Von Willebrand disease and other bleeding disorders in women: Consensus on diagnosis and management from an international expert panel. Am J Obstet Gynecol 2009; 201: 12.e1-8.
16. Asaf T, Reuveni H, Yermiahu T, et al. The need for routine pre-operative coagulation screening tests (prothrombin time PT/partial thromboplastin time PTT for healthy children undergoing elective tonsillectomy and/or adenoidectomy. Int J Ped Otor 2001; 61: 217-22.
17. Segal JB, Dzik WH. Transfusion Medicine/ Hemostasis Clinical Trials Network. Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedures: An evidence-based review. Transfusion 2005; 45: 1413-25.
18. Societá Italiana per lo Studio dell'Emostasi e della Trombosi (SISET). Valutazione del rischio emorragico in pazienti sottoposti ad interventi chirurgici o procedure invasive. SISET; 2007. Available at: Http:// www.siset.org/lineeguida/LG3.pdf. Last accessed: 25/03/2010.
19. Liumbruno G, Bennardello F, Lattanzio A, et al. Recommendations for the transfusion of plasma and platelets. Blood Transfus 2009; 7: 132-50.
20. Schiffer AC, Anderson KC, Bennet CL, et al. Platelet transfusion for patients with cancer: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19: 1519-38.
21. Livio M, Gotti E, Marchesi D, et al. Uraemic bleeding: Role of anaemia and beneficial effect of red cell transfusions. Lancet 1982; 2: 1013-5.
22. Small M, Lowe GD, Cameron E, Forbes CD. Contribution of the haematocrit to the bleeding time. Haemostasis 1983; 13: 379-84.
23. Fernandez F, Goudable C, Sie P, et al. Low haematocrit and prolonged bleeding time in uraemic patients: Effect of red cell transfusions. Br J Haematol 1985; 59: 139-48.
24. Escolar G, Garrido M, Mazzara R, et al. Experimental basis for the use of red cell transfusion in the management of anemic-thrombocytopenic patients. Transfusion 1988; 28: 406-11.
25. Burns ER, Lawrence C. Bleeding time. A guide to its diagnostic and clinical utility. Arch Pathol Lab Med 1989; 113: 1219-24.
26. Ho CH. The hemostatic effect of adequate red cell transfusion in patients with anemia and thrombocytopenia. Transfusion 1996; 36: 290.
27. Crowley JP, Metzger JB, Valeri CR. The volume of blood shed during the bleeding time correlates with the peripheral venous hematocrit. Am J Clin Pathol 1997; 108: 579-84.
28. Valeri CR, Cassidy G, Pivacek LE, et al. Anemiainduced increase in the bleeding time: Implications for treatment of nonsurgical blood loss. Transfusion 2001; 41: 977-83.
29. Eugster M, Reinhart WH. The influence of the hematocrit on primary haemostasis in vitro. Thromb Haemost 2005; 94: 1213-8.
30. Webert KE, Cook RJ, Sigouin CS, et al. The risk of bleeding in thrombocytopenic patients with acute myeloid leukaemia. Haematologica 2006; 41: 1530-7.
31. Webert KE, Cook RJ, Couban S, et al. A multicenter pilot-randomized controlled trial of the feasibility of an augmented red blood cell transfusion strategy for patients treated with induction chemotherapy for acute leukemia or stem cell transplantation. Transfusion 2008; 48: 81-91.
32. Samama CM, Ozier Y. Near-patient testing of haemostasis in the operating theatre: An approach to appropriate use of blood in surgery. Vox Sang 2003; 84: 251-5.
33. Waters JH. Perioperative Blood Management. A Physician's Handbook. 1st ed, Bethesda, MD, AABB; 2006.
34. Federici AB, Castaman G, Thompson A, et al. Von Willebrand disease: Clinical management. Haemophilia 2006; 12 (Suppl 3): 152-8.
35. Nichols WL, Hultin MB, James AH, et al. von Willebrand disease (vWD): Evidence-based diagnosis and management guidelines, the National Heart, Lung and Blood Institute (NHLBI Expert Panel report (USA). Haemophilia 2008; 14: 171-232.
36. Nichols WL, Rick ME, Ortel TL, et al. Clinical and laboratory diagnosis of von Willebrand disease: A synopsis of the 2008 NHLBI/NIH guidelines. Am J Haematol 2009; 84: 366-70.
37. Metjian AD, Wang C, Sood SL, et al. Bleeding symptoms and laboratory correlation in patients with severe von Willebrand disease. Haemophilia 2009; 15: 1-8.
38. Lim W, Moffat K, Hayward CP. Prophylactic and perioperative replacement therapy for acquired factor XIII deficiency. J Thromb Haemost 2004; 2: 1017-9.
39. Answar R, Miloszewski KJ. Factor XIII deficiency. Br J Haematol 1999; 107: 468-84.
40. Keeling D, Tait C, Makris M. Guidelines on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. Haemophilia 2008; 14: 671-84.
41. Santagostino E. Linee guida per la terapia sostitutiva dell'emofilia e dei difetti ereditari della coagulazione. Associazione Italiana dei Centri Emofilia, 2003. Available at: Http://www.aiceonline.it/documenti/LineeGuida/ ITALIA-Coagulopatie.pdf. Last accessed: 25/03/2010.
42. Mannucci PM, Franchini M, Castaman G, et al. Evidence-based recommendations on the treatment of von Willebrand disease in Italy. Blood Transfus 2009; 7: 117-26.
43. Lethagen S, Kyrle PA, Castaman G, et al. The Haemate P Surgical Study Group. Von Willebrand factor/factor VIII concentrate (Haemate P dosing based on pharmacokinetics: A prospective multicenter trial in elective surgery. J Thromb Haemost 2007; 5: 1420-30.
44. Federici AB, Castaman G, Franchini M, et al. Clinical use of Haemate P in inherited von Willebrand disease: A cohort study on 100 Italian patients. Haematologica 2007; 92: 944-51.
45. Borel-Derlon A, Federici AB, Roussel-Robert V, et al. Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin® ): A prospective study of 50 patients. J Thromb Haemost 2007; 5: 1115-24.
46. British Committee for Standards in Haematology. Guidelines for the use of platelet transfusions. Br J Haematol 2003; 122: 10-23.
47. Bosly A, Muylle L, Noens L, et al. Guidelines for the transfusion of platelets. Acta Clin Belg 2007; 62: 36-47.
48. Rebulla P, Finazzi G, Marangoni F, et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. N Engl J Med 1997; 337: 1870-5.
49. Rebulla P. Platelet transfusion trigger in difficult patients. Transfus Clin Biol 2001; 8: 249-54.
50. Tosetto A, Balduini CL, Cattaneo M, et al. Management of bleeding and of invasive procedures in patients with platelet disorders and/or thrombocytopenia: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). Thromb Res 2009; 124: E13-8.
51. American Society of Anesthesiologists Task Force on Obstetric Anesthesia. Practice guidelines for obstetric anesthesia: An updated report by the American Society of Anesthesiologists Task Force on Obstetric Anesthesia. Anesthesiology 2007; 106: 843-63.
52. Levi M, Toh CH, Thachil J, Watson HG. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br J Haematol 2009; 145: 24-33.
53. Callow CR, Swindell R, Randall W, Chopra R. The frequency of bleeding complications in patients with haematological malignancy following the introduction of a stringent prophylactic platelet transfusion policy. Br J Haematol 2002; 118: 677-82.
54. British Committee for Standards in Haematology. Guidelines on the management of massive blood loss. Br J Haematol 2006; 135: 634-41.
55. Levi M. Current understanding of disseminated intravascular coagulation. Br J Haematol 2004; 124: 567-76.
56. Gringeri A. Linee guida per la diagnosi ed il trattamento di pazienti con inibitori dei fattori plasmatici della coagulazione. Associazione Italiana dei Centri Emofilia, 2004. Available at: Http:// www.aiceonline.it/documenti/ LineeGuida/AICE-guida-inib-2004-finale.pdf. Last accessed: 25/03/2010.
57. Hay CR, Brown S, Collins PW, et al. The diagnosis and management of factor VIII and IX inhibitors: A guideline from the United Kingdom Haemophilia Centre Doctors Organisation. Br J Haematol 2006; 133: 591-605.
58. Bolton-Maggs PH, Perry DJ, Chalmers EA, et al. The rare coagulation disorders: Review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation. Haemophilia 2004; 10: 593-628.
59. Peyvandi F, Palla R, Menegatti M, Mannucci PM. Introduction. Rare bleeding disorders: General aspects of clinical features, diagnosis, and management. Semin Thromb Hemost 2009; 35: 349-55.
60. Miller Y, Bachowski G, Benjamin R, et al. Practice Guidelines for Blood Transfusion. A Compilation from Recent Peer-Reviewed Literature. 2nd ed, American National Red Cross; 2007. Available at: Http:// www.redcross.org/www- files/Documents/ W o r k i n g W i t h t h e R e d C r o s s / practiceguidelinesforbloodtrans.pdf. Last accessed: 25/03/2010.
61. Ranucci M, Isgró G, Soro G, et al. Efficacy and safety of recombinant activated factor VII in major surgical procedures. Arch Surg 2008; 143: 296-304.
62. Mannucci PM, Levi M. Prevention and treatment of major blood loss. N Engl J Med 2007; 356: 2301-11.
63. Cardone D, Klein AA. Perioperative blood conservation. Eur J Anaesthesiol 2009; 26: 722-9.
64. Vincent JL, Rossaint R, Riou B, et al. Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding: A European perspective. Crit Care 2006; 10: R120.
65. Shander A, Goodnough LT, Ratko T, et al. Consensus recommendations for the off-label use of recombinant human factor VIIa (NovoSeven therapy. Pharma Ther 2005; 30: 644-58.
66. Welsh A, McLintock C, Gatt S, et al. Guidelines for the use of recombinant activated factor VII in massive obstetric haemorrhage. Aust N Z J Obstet Gynaecol 2008; 48: 12-6.
67. Stanworth SJ, Birchall J, Doree CJ, Hyde C. Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Database Syst Rev 2007; 2: CD005011.
68. European Medicines Agency. NovoSeven. European Public Assessment Report. Procedural steps taken and scientific information after the authorization. Changes made after 01/02/2004. Available at: Http:// www.ema.europa.eu/docs/en- GB/document-library/EPAR-Procedural-steps-taken-and-scientific-information- after-authorisation/human/000074/ WC500030872.pdf. Last accessed 11/01/2010.
69. European Medicines Agency. NovoSeven. Allegato I. Riassunto delle caratteristiche del prodotto. Available at: Http://www.ema.europa.eu/docs/it-IT/ document-library/EPAR-Product-Information/ human/000074/WC500030873.pdf. Last accessed: 11/ 01/2010.
70. Carless PA, Stokes BJ, Moxey AJ, et al. Desmopressin use for minimising perioperative allogeneic blood transfusion. Cochrane Database Sys Rev 2004; 1: CD 001884.
71. Mannucci PM. Desmopressin: An historical introduction. Haemophilia 2008; 14 (Suppl 1): 1-4.
72. Franchini M. The use of desmopressin as a hemostatic agent: A concise review. Am J Hemat 2007; 82: 731-5.
73. Cattaneo M. The use of desmopressin in open-heart surgery. Haemophilia 2008; 14 (Suppl 1): 40-7.
74. German Medical Association. Cross-Sectional Guidelines for Therapy with Blood Components and Plasma Derivatives. 4th revised edition; 2009. Available at: Http://www.bundesaerztekammer.de/ downloads/LeitCrossBloodComponents4ed.pdf. Last accessed: 25/03/2010.
75. Liumbruno GM, Bennardello F, Lattanzio A, et al. Recommendations for the use of antithrombin concentrates and prothrombin complex concentrates. Blood Transfus 2009; 7: 325-34.
76. Hathaway WE, Goodnight SH Jr. Malattie dell'Emostasi e Trombosi. Milano, McGraw-Hill Companies Italia; 1994.
77. Afshari A, Wetterslev J, Brok J, Møller AM. Antithrombin III for critically ill patients. Cochrane Database Syst Rev 2008; 3: CD005370.
78. Afshari A, Wetterslev J, Brok J, Møller A. Antithrombin III in critically ill patients: Systematic review with meta-analysis and trial sequential analysis. BMJ 2007; 335: 1248-51.
79. Roberts HR, Monroe DM, Escobar MA. Current concepts of hemostasis: Implication for therapy. Anesthesiology 2004; 100: 722-30.
80. Russell MW, Jobes D. What should we do with aspirin, NSAIDs, and glycoprotein-receptor inhibitors? Int Anesthesiol Clin 2002; 40: 63-76.
81. Schroeder WS, Gandhi PJ. Emergency management of hemorragic complications in the era of glycoprotein IIb/IIIa receptor antagonists, clopidogrel, low molecular weight heparin, and third-generation fibrinolytic agents. Curr Cardiol Rep 2003; 5: 310-7.
82. Patrono C, Rocca B. Aspirin 110 years later. J Thromb Haemost 2009; 7 (Suppl 1): 258-61.
83. Strom BL, Berlin JA, Kinman JL, et al. Parenteral ketorolac and risk of gastrointestinal and operative site bleeding. A postmarketing surveillance study. JAMA 1996; 275: 376-82.
84. Dunning J, Versteegh M, Fabbri A, et al. Guidelines on antiplatelet and anticoagulation management in cardiac surgery. Eur J Cardiothorac Surg 2008; 34: 73-92.
85. Lecompte T, Hardy F. Antiplatelets agents and perioperative bleeding. Can J Anesth; 53: S103-16.
86. Gresele P. Perioperative handling of antiplatelet therapy: Watching the two sides of the coin. Intern Emerg Med 2009; 4: 275-6.
87. Di Minno NMD, Prisco D, Ruocco AL, et al. Perioperative handling of patients on antiplatelet therapy with need for surgery. Intern Emerg Med 2009; 4: 279-88.
88. Dunn AS, Turpie AG. Perioperative management of patients receiving oral anticoagulants: A systematic review. Arch Intern Med 2003; 163: 901-8.
89. NIH -Consensus Conference. Fresh-frozen plasma. Indications and risks. JAMA 1985; 253: 551-3.
90. British Committee for Standards in Haematology. Guidelines for the use of fresh frozen plasma. Transfus Med 1992; 2: 57-63.
91. Vorstand und wissenschaftlicher Beirat der Bundesärztekammer. Gefrorenes Frischplasma. In: Leitlinien zur Therapie mit Blutkomponenten und Plasmaderivaten (Revision 2003). Köln, Deutscher ärzte-Verlag; 2003.
92. Ortiz P, Mingo A, Lozano M, et al. Guide for transfusion of blood components. Med Clin (Barc 2005; 125: 389-96.
93. Stanworth SJ, Brunskill SJ, Hyde CJ, et al. Appraisal of the evidence for the clinical use of FFP and plasma fractions. Best Pract Res Clin Haematol 2006; 19: 67-82.
94. Dzik WH. The NHLBI Clinical Trials Network in transfusion medicine and hemostasis: An overview. J Clin Apher 2006; 21: 57-9.
95. Warkentin TE, Crowther MA. Reversing anticoagulants both old and new. Can J Anaesth 2002; 49 (Suppl): S11-25.
96. Douketis JD, Johnson JA, Turpie AG. Low molecularweight heparin as bridging anticoagulation during interruption of warfarin: Assessment of a standardized periprocedural anticoagulation regimen. Arch Intern Med 2004; 164: 1319-26.
97. Cohen AT, Hirst C, Sherril B, et al. Meta-analysis of trials comparing ximelagatran with low molecular weight heparin for prevention of venous thromboembolism after major orthopaedic surgery. Br J Surg 2005; 92: 1335-44.
98. O'Donnell M, Linkins LA, Kearon C, et al. Reduction of out-of-hospital symptomatic venous thromboembolism by extended thromboprophylaxis with low-molecular-weight heparin following elective hip arthroplasty: A systematic review. Arch Intern Med 2003; 163: 1362-6.
99. Kuczkowski KM. Labor analgesia for the parturient with herbal medicines use: What does an obstetrician need to know? Arch Gynecol Obstet 2006; 274: 233-9.
100. Wang SM, Caldwell-Andrews AA, Kain ZN. The use of complementary and alternative medicines bysurgical patients: A follow-up survey study. Anesth Analg 2003; 97: 1010-5.
101. Kaye AD, Clarke RC, Sabar R, et al. Herbal medicines: Current trends in anesthesiology practice. A hospital survey. J Clin Anesth 2000; 12: 468-71.
102. Cheng B, Hung CT, Chiu W. Herbal medicine and anaesthesia. Hong Kong Med J 2002; 8: 123-30.
103. Tsen LC, Segal S, Pothier M, et al. Alternative medicine use in presurgical patients. Anesthesiology 2000; 93: 148-51.
104. Ang-Lee MK, Moss J, Yuan CS. Herbal medicines and perioperative care. JAMA 2001; 286: 208-16.
105. German K, Kumar U, Blackford HN. Garlic and the risk of TURP bleeding. Br J Urol 1995; 76: 518.
106. Liumbruno G, Bennardello F, Lattanzio A, et al. Recommendations for the transfusion of red blood cells. Blood Transfus 2009; 7: 49-64.
107. Gurusami KS, Osmani B, Shara, et al. Non-surgical interventions to decrease blood loss and blood transfusion requirements for liver resection. Cochrane Database Syst Rev 2008; 3: CD7378.
108. Smoller BR, Krushall MS. Phlebotomy for diagnostic laboratory tests in adults: Pattern of use and effect on transfusion requirements. N Engl J Med 1986; 314: 1233-5.
109. Alvarez GG, Fergusson DA, Neilpovitz DT, et al. Cell salvage does not minimize perioperative allogeneic blood transfusion in abdominal vascular surgery: A systematic review. Can J Anesth 2004; 51: 425-31.
110. Tinmouth AT, McIntyre LA, Fowler RA. Blood conservation strategies to reduce the need for red blood cell transfusion in critically ill patients. CMAJ 2008; 178: 49-57.
111. Napolitano LM. Perioperative anemia. Surg Clin N Am 2005; 85: 1215-27.
112. Shermack KM, Horn E, Rice TL. Erythropoietic agents for anemia of critical illness. Am J Health Syst Pharm 2008; 65: 540-6.
113. Goodnough LT, Skine B, Brugnara C. Erythropoietin, iron and erythropoiesis. Blood 2000; 96: 823-33.
114. Crosby E. Perioperative use of erythropoietin. Am J Ther 2002; 9: 371-6.
115. Corwin HL, Gettinger A, Fabian TC, et al. Efficacy and safety of epoetin alfa in critically ill patients. N Eng J Med 2007; 357: 965-76.
116. Goodnough LT, Marcus RE. Erythropoiesis in patients stimulated with erythropoietin: The relevance of storage iron. Vox Sang 1998; 75: 128-33.
117. Madore F, Whiter CT, Foley RB, et al. Clinical practice guidelines for assessment and management of iron deficiency. Kidney Int 2008; 74 (Suppl 110): S7-S11.
118. Goodnough LT, Verbrugge D, Marcus RE, et al. The effect of patient size and dose of recombinant human erythropoietin therapy on red blood cell expansion. J Am Coll Surg 1994; 179: 171-6.
119. Goodnough LT, Price TH, Parvin CA. The endogenous erythropoietin response and the erythropoietic response to blood loss anemia: The effects of age and gender. J Lab Clin Med 1995; 126: 57-64.
120. Beris P, Munoz M, Garcia-Erce JA, et al. Perioperative anemia management: Consensus statement on the role of intravenous iron. Br J Anesth 2008; 100: 599-604.
121. Auerbach M, Goodnough LT, Picard D, et al. The role of intravenous iron in anemia management and transfusion avoidance. Transfusion 2008; 48: 988- 1000.
122. Auerbach M, Coyen D, Ballard H. Intravenous iron: From anathema to standard of care. Am J Hematol 2008; 83: 580-8.
123. Fishbane S, Ungureanu VD, Maeska JK, et al. The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis 1996; 28: 529-34.
124. Kim YH, Chung HH, Kang SB, et al. Safety and usefulness of intravenous iron sucrose in the management of preoperative anemia in patients with menorrhagia: A phase IV, open label, prospective, randomized study. Acta Haematol 2009; 121: 37-41.
125. Fishbane S. Safety in iron management. Am J Kidney Dis 2003; 41: S18-26.
126. Hayat A. Safety issues with intravenous iron products in the management of anemia in chronic kidney disease. Clin Med Res 2008; 34: 93-102.
127. Aronoff GR. Safety of intravenous iron in clinical practice: Implications for anemia management protocols. J Am Soc Nephrol 2004; 15: S99-106.
128. Notebaert E, Chauny JM, Albert M, et al. Short-term benefits and risks of intravenous iron: A systematic review and meta-analysis. Transfusion 2007; 47: 1905-18.